Chengjun Zhu1, Hua Shen1, Lingjun Zhu1, Feng Zhao2, Yongqian Shu1. 1. Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2. Department of Ultrasonography, Affiliated of Jiangsu University, Zhenjiang, China.
Abstract
BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis. Since it has been shown that PAI-1 can activate macrophages through Toll-like receptor-4, we sought to investigate the role of PAI-1 in the tumor microenvironment. METHODS: The expression and distribution patterns of PAI-1 and transforming growth factor beta (TGF-β) were measured in 60 non-small cell lung cancer (NSCLC) tumors. A statistical correlation analysis was performed between PAI-1 and TGF-β expression and distribution in each tumor. The distribution of tumor-associated macrophages (TAMs) was also measured and its correlation to PAI-1 levels was analyzed. Levels of secreted CCL-17, CCL-22, IL-6 and TGF-β were measured in cell cultures of human macrophage cell lines THP-1 and U937 treated with PAI-1. Levels of secreted PAI-1 were monitored in cell cultures of human NSCLCs cell lines 95D and A549 treated with TGF-β. Secreted proteins were measured in cell culture supernatants using ELISA. Changes in downstream signaling pathways were investigated using western blot. RESULTS: PAI-1 and TGF-β were found to be overexpressed in human NSCLCs. PAI-1 expression was tightly correlated to TGF-β expression as well as the percentage of TAMs. PAI-1 treatment increased the expression of TAM-associated cytokines and chemokines, including CCL-17, CCL-22, and IL-6. PAI-1 treatment was also observed to enhance TGF-β expression in macrophage cell lines through an IL-6 autocrine/paracrine manner. The effects on TGF-β expression were blocked by NF-κB and STAT3 inhibition. Interestingly, TGF-β also increased levels of secreted PAI-1 in NSCLC cells through SMAD3-dependent signaling, therefore resulting in a feed-forward loop. However, this loop could be blocked by NF-κB, STAT3 and SMAD3 signaling inhibition, as well as treatment with a high concentration of TGF-β. CONCLUSION: PAI-1 and TGF-β promote NSCLC tumor cells and TAMs and might be valuable targets for cancer immunosuppression.
BACKGROUND:Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis. Since it has been shown that PAI-1 can activate macrophages through Toll-like receptor-4, we sought to investigate the role of PAI-1 in the tumor microenvironment. METHODS: The expression and distribution patterns of PAI-1 and transforming growth factor beta (TGF-β) were measured in 60 non-small cell lung cancer (NSCLC) tumors. A statistical correlation analysis was performed between PAI-1 and TGF-β expression and distribution in each tumor. The distribution of tumor-associated macrophages (TAMs) was also measured and its correlation to PAI-1 levels was analyzed. Levels of secreted CCL-17, CCL-22, IL-6 and TGF-β were measured in cell cultures of human macrophage cell lines THP-1 and U937 treated with PAI-1. Levels of secreted PAI-1 were monitored in cell cultures of human NSCLCs cell lines 95D and A549 treated with TGF-β. Secreted proteins were measured in cell culture supernatants using ELISA. Changes in downstream signaling pathways were investigated using western blot. RESULTS:PAI-1 and TGF-β were found to be overexpressed in human NSCLCs. PAI-1 expression was tightly correlated to TGF-β expression as well as the percentage of TAMs. PAI-1 treatment increased the expression of TAM-associated cytokines and chemokines, including CCL-17, CCL-22, and IL-6. PAI-1 treatment was also observed to enhance TGF-β expression in macrophage cell lines through an IL-6 autocrine/paracrine manner. The effects on TGF-β expression were blocked by NF-κB and STAT3 inhibition. Interestingly, TGF-β also increased levels of secreted PAI-1 in NSCLC cells through SMAD3-dependent signaling, therefore resulting in a feed-forward loop. However, this loop could be blocked by NF-κB, STAT3 and SMAD3 signaling inhibition, as well as treatment with a high concentration of TGF-β. CONCLUSION:PAI-1 and TGF-β promote NSCLC tumor cells and TAMs and might be valuable targets for cancer immunosuppression.
Authors: Sandra Muñoz-Galván; Maria Rivero; Javier Peinado-Serrano; Julia Martinez-Pérez; M C Fernández-Fernández; María José Ortiz; José M García-Heredia; Amancio Carnero Journal: Cells Date: 2020-04-25 Impact factor: 6.600
Authors: Ashley Maynard; Caroline E McCoach; Julia K Rotow; Lincoln Harris; Franziska Haderk; D Lucas Kerr; Elizabeth A Yu; Erin L Schenk; Weilun Tan; Alexander Zee; Michelle Tan; Philippe Gui; Tasha Lea; Wei Wu; Anatoly Urisman; Kirk Jones; Rene Sit; Pallav K Kolli; Eric Seeley; Yaron Gesthalter; Daniel D Le; Kevin A Yamauchi; David M Naeger; Sourav Bandyopadhyay; Khyati Shah; Lauren Cech; Nicholas J Thomas; Anshal Gupta; Mayra Gonzalez; Hien Do; Lisa Tan; Bianca Bacaltos; Rafael Gomez-Sjoberg; Matthew Gubens; Thierry Jahan; Johannes R Kratz; David Jablons; Norma Neff; Robert C Doebele; Jonathan Weissman; Collin M Blakely; Spyros Darmanis; Trever G Bivona Journal: Cell Date: 2020-08-20 Impact factor: 41.582
Authors: Toshifumi Matsuyama; Shawn P Kubli; Steven K Yoshinaga; Klaus Pfeffer; Tak W Mak Journal: Cell Death Differ Date: 2020-10-09 Impact factor: 15.828